Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Burlington, VT
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Burlington, VT
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Self-Management and Care of Heart Failure With Group Clinics (SMAC-HF)
HF Group Clinic Appointments: Rehospitalization Prevention
Status: Archived
University of Kansas Medical Center
mi
from
Kansas City, KA
Self-Management and Care of Heart Failure With Group Clinics (SMAC-HF)
HF Group Clinic Appointments: Rehospitalization Prevention
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
mi
from
Kansas City, KA
HEROIC (Heparin Requirement in Counterpulsation)
Heparin Requirement in Counterpulsation
Status: Archived
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
HEROIC (Heparin Requirement in Counterpulsation)
Heparin Requirement in Counterpulsation
Status: Archived
Updated: 1/1/1970
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Biomarker Study for Heart Failure in Children With Single Ventricle Physiology
Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology
Status: Archived
Achieve Clinical Research
mi
from
Birmingham, AL
Biomarker Study for Heart Failure in Children With Single Ventricle Physiology
Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology
Status: Archived
Updated: 1/1/1970
Achieve Clinical Research
mi
from
Birmingham, AL
A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan
A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan
Status: Archived
Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital
mi
from
Houston, TX
A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan
A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan
Status: Archived
Updated: 1/1/1970
Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital
mi
from
Houston, TX
Effect on Bleeding When Using FloSeal Matrixâ„¢ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
Effect on Bleeding When Using FloSeal Matrixâ„¢ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Effect on Bleeding When Using FloSeal Matrixâ„¢ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
Effect on Bleeding When Using FloSeal Matrixâ„¢ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Juels Stein Eye Institute
mi
from
Los Angeles, CA
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Juels Stein Eye Institute
mi
from
Los Angeles, CA
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Southern California Desert Retina Consultants
mi
from
Palm Desert, CA
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Black Hills Eye Institute
mi
from
Rapid City, SD
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Status: Archived
Updated: 1/1/1970
Black Hills Eye Institute
mi
from
Rapid City, SD
Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques
Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques
Status: Archived
University of California Irvine, 101 The City Drive S, Bldg. 22 C, Route 13
mi
from
Orange, CA
Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques
Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques
Status: Archived
Updated: 1/1/1970
University of California Irvine, 101 The City Drive S, Bldg. 22 C, Route 13
mi
from
Orange, CA
Post-conditioning to Reduce Infarct Size
Modification of Reperfusion by "Post-Conditioning" Reduces Infarct Size in Acute Myocardial Infarction
Status: Archived
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Post-conditioning to Reduce Infarct Size
Modification of Reperfusion by "Post-Conditioning" Reduces Infarct Size in Acute Myocardial Infarction
Status: Archived
Updated: 1/1/1970
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Morehouse CRC
mi
from
Atlanta, GA
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Morehouse CRC
mi
from
Atlanta, GA
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Minnesota Heart Failure Network
mi
from
Minneapolis, MN
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Minnesota Heart Failure Network
mi
from
Minneapolis, MN
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
University Of Utah Hospital
mi
from
Salt Lake City, UT
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
University Of Utah Hospital
mi
from
Salt Lake City, UT
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Maintenance of Platelet Inhibition With Cangrelor
BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry
Status: Archived
Scripps HealthCare
mi
from
LaJolla, CA
Maintenance of Platelet Inhibition With Cangrelor
BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry
Status: Archived
Updated: 1/1/1970
Scripps HealthCare
mi
from
LaJolla, CA
Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery
Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities
Status: Archived
New England Baptist Hospital
mi
from
Boston, MA
Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery
Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities
Status: Archived
Updated: 1/1/1970
New England Baptist Hospital
mi
from
Boston, MA
The Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation
Determining the Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
The Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation
Determining the Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing
Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing in Non-paralyzed Adult Patients Under General Anesthesia
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing
Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing in Non-paralyzed Adult Patients Under General Anesthesia
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)
Phase II Study for the Transfer of Bone Marrow-Derived Mononuclear and Mesenchymal StemCells Into the Myocardium for the Treatment of Severe Coronary Ischemia
Status: Archived
TCA Cellular Therapy
mi
from
Covington, LA
Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)
Phase II Study for the Transfer of Bone Marrow-Derived Mononuclear and Mesenchymal StemCells Into the Myocardium for the Treatment of Severe Coronary Ischemia
Status: Archived
Updated: 1/1/1970
TCA Cellular Therapy
mi
from
Covington, LA
Pegaptanib Therapy in Uveitis
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Pegaptanib Therapy in Uveitis
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval
A Pilot Study of theRelationship Between Atrio-Ventricular Delay and Changes in Biochemical Markers of Chronic Heart Failure During Cardiac Resynchronization Therapy (BRAVO-CRT)
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval
A Pilot Study of theRelationship Between Atrio-Ventricular Delay and Changes in Biochemical Markers of Chronic Heart Failure During Cardiac Resynchronization Therapy (BRAVO-CRT)
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation
The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation
Status: Archived
University of Kansas Medical Center
mi
from
Kansas City, KA
Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation
The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
mi
from
Kansas City, KA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Norman Garrison
mi
from
Montgomery, AL
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Norman Garrison
mi
from
Montgomery, AL
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Centinela Hospital
mi
from
Inglewood, CA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Centinela Hospital
mi
from
Inglewood, CA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Louisiana State University
mi
from
New Orleans, LA
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)
Status: Archived
Updated: 1/1/1970
Louisiana State University
mi
from
New Orleans, LA